TY - JOUR
T1 - The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells
AU - Gaynor, E. R.
AU - Vitek, L.
AU - Sticklin, L.
AU - Creekmore, S. P.
AU - Ferraro, M. E.
AU - Thomas, J. X.
AU - Fisher, S. G.
AU - Fisher, R. I.
PY - 1988
Y1 - 1988
N2 - In 1976, Morgan and colleagues first described the T-cell growth factor, interleukin-2, which is a glycoprotein with several in-vitro and in-vivo immunoregulatory effects. In addition to enhancing natural killer cell function, the incubation of peripheral blood lymphocytes with interleukin-2 results in the generation of lymphokine-activated killer cells. Lymphokine-activated killer cells can lyse fresh, autologous, or syngeneic tumor cells but show no lytic activity toward normal cells. The selective destruction of tumor cells thus theoretically provides the ideal cancer therapy: that is, one that destroys tumor cells while leaving normal host cells unharmed. Unfortunately, significant toxicity has limited the amount of interleukin-2 that can be safely administered to humans. Clearly, one of the most significant toxicities associated with interleukin-2 therapy is its effect on the cardiovascular system. Because of this predictable hemodynamic toxicity of interleukin-2 and because of its clinical importance, we studied the hemodynamic alterations occurring during interleukin-2 therapy in 13 patients.
AB - In 1976, Morgan and colleagues first described the T-cell growth factor, interleukin-2, which is a glycoprotein with several in-vitro and in-vivo immunoregulatory effects. In addition to enhancing natural killer cell function, the incubation of peripheral blood lymphocytes with interleukin-2 results in the generation of lymphokine-activated killer cells. Lymphokine-activated killer cells can lyse fresh, autologous, or syngeneic tumor cells but show no lytic activity toward normal cells. The selective destruction of tumor cells thus theoretically provides the ideal cancer therapy: that is, one that destroys tumor cells while leaving normal host cells unharmed. Unfortunately, significant toxicity has limited the amount of interleukin-2 that can be safely administered to humans. Clearly, one of the most significant toxicities associated with interleukin-2 therapy is its effect on the cardiovascular system. Because of this predictable hemodynamic toxicity of interleukin-2 and because of its clinical importance, we studied the hemodynamic alterations occurring during interleukin-2 therapy in 13 patients.
UR - http://www.scopus.com/inward/record.url?scp=0024203907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024203907&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-109-12-953
DO - 10.7326/0003-4819-109-12-953
M3 - Article
C2 - 3264128
AN - SCOPUS:0024203907
SN - 0003-4819
VL - 109
SP - 953
EP - 958
JO - Annals of internal medicine
JF - Annals of internal medicine
IS - 12
ER -